TL;DR
Bad news was good news: a weak US June jobs report (+57k vs a 115k Dow Jones consensus) killed the Fed-hike scare, sending the Dow to a record and the FTSE 100 to a four-month high — but the AI/semiconductor complex sold off hard on valuation fears, leaving the tape split.
The macro tension is inflation vs. jobs: core PCE sits at a 3-year-high 3.4% while hiring stalls, so Fed Chair Kevin Warsh is holding at 3.50–3.75% and refusing forward guidance; the dollar has been firm (DXY ~101) but slipped on the jobs miss.
This week's deep dive is Robinhood (HOOD): riding record June volumes, a new blockchain, and the 4 July launch of the government-backed "Trump Accounts" — bull case is diversification and crypto optionality, bear case is a rich valuation already pricing a lot of good news.
Key Findings
Indices split. For the holiday-shortened week (US markets closed Fri 3 July for Independence Day), the S&P 500 gained ~1.8%, the Nasdaq ~2.1% and the Dow ~2%. The Dow closed at a record 52,900; the Nasdaq lagged as chips fell.
Jobs cooled sharply. June nonfarm payrolls +57k (lowest in four months), unemployment 4.2%, wages +3.5% y/y. April/May revised down a combined 74k. September hike odds fell to ~50% from ~64–67%.
Inflation still hot. Core PCE 3.4% (highest since Oct 2023), headline PCE 4.1% (3-year high) — driven by the Iran-war energy spike now fading. Eurozone flash CPI cooled to 2.8%.
Warsh at Sintra: hawkish-but-flexible. "We're going to deliver price stability." Buried forward guidance alongside Lagarde, Bailey and Macklem.
AI capex is enormous but under scrutiny. The four US hyperscalers guide to ~$725bn of 2026 capex (+77% y/y). Yet chips sold off ~5–13% mid-week on HBM/valuation fears.
HOOD: Q1 2026 revenue $1.07bn (+15%), crypto down 47%, prediction markets +320%. Stock ~$108 after a record June; launched its own blockchain and the Trump Accounts app.
Details
SECTION 1 — News Recap (week of 29 June – 3 July 2026)
Index scoreboard (week to Thursday 2 July close; US shut Friday 3 July):
Index | Level | Weekly move |
|---|---|---|
S&P 500 | 7,483 | +1.8% |
Nasdaq Composite | 25,833 | +2.1% (Nasdaq 100 fell ~2% Thursday) |
Dow Jones | 52,900 | +2% (record high) |
Russell 2000 | 2,996 | roughly flat / −0.5% Thursday |
FTSE 100 | 10,673 (Fri 3 July close) | four-month high; +1.7% Thursday to 10,653 |
The week's defining feature was a rotation: the Dow hit a record on strength in traditionals (Apple +4.8% Thursday, Visa and Walmart ~+3%) while the AI/semiconductor complex was hammered. On Thursday 2 July the Nasdaq 100 fell ~2% as Micron sank ~7%, Applied Materials ~7.4%, AMD ~4.3%, and Tesla fell ~7.5% despite strong deliveries. Meta fell ~5% after saying it may monetise excess compute capacity — read by some as a sign capex was overdone. There were also reports OpenAI was in talks to sell a ~5% stake to the US government.
The June jobs report (released Thursday 2 July, pulled forward from Friday due to the 4 July holiday):
Per the BLS Employment Situation release (USDL-26-1125): "Both total nonfarm payroll employment (+57,000) and the unemployment rate (4.2 percent) changed little in June." The 115,000 Dow Jones consensus (CNBC) was badly missed — the weakest gain in four months.
Unemployment 4.2% (down from 4.3%), but the dip was low-quality: labour-force participation slipped 0.3pp to 61.5%, its lowest since March 2021, driven by roughly 720,000 workers leaving the labour force and 507,000 fewer employed in the household survey.
Average hourly earnings +0.3% m/m, +3.5% y/y to $37.64.
April revised down 31k (to 148k); May revised down 43k (to 129k) — combined 74k lower.
Leisure & hospitality lost 61,000 jobs (weak seasonal hiring, possibly a World Cup effect); gains in professional/business services (+36k), social assistance (+25k), health care (+22k).
Reaction: stock futures rose, the 2-year yield fell ~3.5bp to 4.13%, and September hike odds dropped to ~50% from ~64%.
Other data that week:
ADP (Wed 1 July): +98,000 private jobs — also soft.
ISM Manufacturing (June): 53.3 (down from 54.0), sixth straight month of expansion but below the ~53.8 consensus; the prices index fell sharply to 73.0 from 82.1 — notable inflation relief.
ISM Services: most recent print 54.5 (May); the June figure was due the week of 6 July.
Eurozone flash CPI (June): 2.8% (down from 3.2%, below the 3.0% consensus); core 2.4%. Germany 2.4%, France 2.0%, Italy 3.1%, Spain 3.6%.
UK: FTSE 100 hit a four-month high; defence names (BAE, Babcock, QinetiQ, Melrose) rallied on a £15bn UK defence-spending plan; EasyJet surged >10% on a fifth Castlelake takeover bid.
Rates, dollar, commodities, crypto (levels around 2 July):
US 10-year yield: ~4.46–4.49%, easing on the jobs miss (2-year to 4.13%).
DXY: ~101 area; slipped toward 100.8 on the jobs data — on track to snap a two-week win streak and post its biggest weekly drop since April.
Gold: broke above $4,100, reaching ~$4,170 (highest since 23 June), ~+2% on the week, as rate-hike odds fell.
Oil: Brent ~$71.5, WTI ~$68 — near pre-Iran-war lows as Strait of Hormuz shipping normalised and OPEC+ supply concerns grew.
Bitcoin: ~$61,000–$62,800 — subdued, after what CoinDesk called "its toughest June since 2022."
Geopolitics/trade: US–Iran peace talks progressed (Doha mediation via Qatar and Pakistan); Strait of Hormuz shipping recovered, with Saudi exports back to ~90% of pre-war levels. The Supreme Court ruled Fed Governor Lisa Cook could keep her seat despite Trump's attempt to remove her.
SECTION 2 — Macro Outlook: Inflation vs. Jobs, and the Dollar
The core tension. The US economy is showing a classic late-cycle split: inflation is still too high (core PCE 3.4%, headline PCE 4.1% — a 3-year high in May, reported 25 June) while the labour market is visibly cooling (+57k jobs, falling participation). The inflation spike was largely energy-driven by the Iran war; with oil now back near pre-war levels, most economists (UBS, Capital Economics, Nationwide) think May marked the peak, with disinflation resuming in H2 2026. But core services ex-housing has been sticky (~3.7%), and tariffs are still passing through.
Fed path. At the 16–17 June meeting, the Fed held at 3.50–3.75% and removed its easing bias; nearly half of the 19 policymakers penciled in a hike this year, eight saw no change, one saw a cut. Warsh (Chair since 22 May) has been hawkish on inflation ("prices are too high"; "we're going to deliver price stability") but at Sintra he stressed inflation expectations had eased, removing the urgency to hike. Net: hold is the base case, with the market pricing ~50% odds of a September hike after the jobs miss (down from ~64–67%). The next meeting is 28–29 July. This is an unusual regime — the Fed's next move is debated between hike and hold, not cut vs hold.
Dollar. DXY broke above 100 in June (highest since May 2025) on the hawkish Fed and hot inflation, and had been in a firming trend, though it slipped to ~100.8–101 on the July jobs miss. Drivers: US rate differentials (2-year yields at 2026 highs), US growth outperformance versus a weak Europe, and periodic safe-haven flows.
What a strong dollar typically means for traders (educational framework):
US multinationals / large-cap tech: headwind — overseas earnings translate into fewer dollars.
Commodities (gold, oil): typically a headwind (priced in dollars) — though gold has defied this on central-bank buying and rate-cut hopes.
Emerging markets: headwind — capital outflows and pressure on dollar-denominated debt.
US domestic small-caps (Russell 2000): relatively insulated (more domestic revenue) but rate-sensitive.
US importers/consumers: tailwind — cheaper imports, lower imported inflation.
SECTION 3 — AI Thematic: Can the AI Names Keep Carrying the Market?
The bull case — capex is staggering and still rising. Per Q1 earnings compiled by the Financial Times, Google, Amazon, Microsoft and Meta "collectively plan to spend $725 billion on capex in 2026, up 77% from last year's record $410 billion." Company-by-company: Amazon ~$200bn, Microsoft ~$190bn (CY2026), Alphabet $175–185bn, Meta $115–135bn (later guided toward $125–145bn). Google cloud revenue jumped 63% y/y to $20bn; Microsoft says it will stay capacity-constrained through 2026. Jefferies' Brent Thill told the FT: "The AI economy is healthy… The bear thesis is garbage." Goldman now models ~$5.3trn of combined hyperscaler capex FY25–FY30, with analysts projecting $1trn+ in 2027.
Valuation context. Nvidia trades around a forward P/E in the low-30s to low-40s (sources vary: ~32x to ~43x) — a premium, but with a PEG near ~0.3 that bulls argue is reasonable given growth. Nvidia's revenue guidance and Blackwell (sold out through mid-2026), plus an accelerated Rubin roadmap, underpin the bull thesis. The stock sat around ~$197 after the selloff, down ~12% on the month but still up year-on-year.
The risks (present in a balanced way):
Valuation/concentration: Nvidia neared a ~$5trn market cap — "little room for error."
The mid-week selloff (30 June–2 July): triggered by a report SK Hynix may slow HBM expansion; Micron −13% (one session), Intel −9%, AMD −7%, the SMH ETF −5% after a record 71% Q2 gain. South Korea's Kospi fell up to ~10% intraday.
Capex-vs-revenue gap: Forbes/CreditSights flag that the gap between spending and monetised AI revenue is widening; Amazon's free cash flow could turn negative. Meta's "monetise excess compute" comment rattled bulls.
Circular financing / power constraints: OpenAI–US-government stake talk; electricity (not chips) is increasingly the binding constraint.
Read-through: The AI trade's fundamentals (demand, backlogs) remain intact, but the tape is now valuation-sensitive and headline-driven. Leadership can persist, but with sharper two-way volatility than in 2024–25.
SECTION 4 — Deep Dive: Robinhood (NASDAQ: HOOD)
Snapshot: Share price ~$108 (2 July, up ~4% that day; intraday high ~$118 after a Mizuho target boost), market cap ~$100bn, P/E ~52x. Down as much as ~30% YTD at points in 2026 but rallied hard into July on record June volumes. Analyst consensus "Buy"/"Strong Buy"; average target ~$105–117 (range $52 low to $155 high). Recent target hikes: Goldman $121, Deutsche Bank $113, BTIG $125, Mizuho (bullish; called HOOD potentially the "first true global hyperscaler of online brokerages"). Q2 2026 results due 29 July.
Latest results (Q1 2026, reported 28 April):
Total net revenue $1.07bn (+15% y/y); net income $346m (+3%); diluted EPS $0.38 (missed by ~$0.01).
Transaction revenue $623m (+7%): options $260m (+8%), equities $82m (+46%), crypto $134m (−47%), other/event contracts $147m (+320%).
Net interest revenue $359m (+24%); Gold subscribers a record 4.3m (+36%); funded customers 27.4m (+6%); total platform assets $307bn (+39%).
Crypto notional volume on the app −48% to $24bn; Bitstamp added $42bn; a record 8.8bn event contracts traded.
The "Trump Accounts" tailwind. Under the 2025 One Big Beautiful Bill Act, the US created "Trump Accounts" (530A accounts) — IRA-style investment accounts for children. Per the IRS, the program provides "$1,000 for children born between Jan. 1, 2025, and Dec. 31, 2028, and who are U.S. citizens with a valid Social Security number"; families can add up to $5,000/yr. In April 2026 the Treasury selected BNY Mellon (administrator) and Robinhood (brokerage/initial trustee/app). Robinhood launched the Trump Accounts app ahead of the 4 July national rollout. A senior Treasury official told NBC News on 3 July that "more than 6 million children have been registered for the accounts, with 1.4 million of those eligible for the $1,000 government seed money." Robinhood added a ~$100m investment to build the UI (raising its FY26 opex guide). Strategic value: a government-backed funnel of long-duration accounts positioned for the "Great Wealth Transfer."
Business expansion (2025–2026): Robinhood has aggressively diversified beyond trading — prediction markets/event contracts (via the Rothera/Susquehanna JV; ~12.3bn contracts through 25 June; one Artemis analyst thinks prediction-market revenue could top crypto revenue in Q2); Robinhood Chain (an Arbitrum-based L2 blockchain launched 1 July at a London event); tokenized stocks in 120+ countries; Robinhood Earn (DeFi lending, ~7% on USDG); perpetual futures in Europe; Robinhood Banking (>$2bn deposits from >125k customers); wealth management (Strategies, TradePMR, 3% IRA match, Platinum Card); private markets (RVI fund); and crypto M&A (Bitstamp closed June 2025; WonderFi in Canada). It also raised $2.2bn in 0% convertible notes due 2029 and announced a 10% (~290-person) workforce cut.
Crypto sensitivity. Robinhood's revenue and stock are historically highly geared to crypto volumes and Bitcoin price — crypto revenue swelled in the 2020–21 and 2025 bull runs and collapsed 47% in Q1 2026 as Bitcoin fell. A crypto-market recovery would be a direct revenue tailwind (and a sentiment tailwind for the stock), but the company is deliberately reducing that dependence via prediction markets, tokenization and net-interest income.
Bull vs Bear (educational):
Bull: Trump Accounts funnel + Great Wealth Transfer; genuine diversification away from volatile trading revenue; crypto optionality if a bull market returns; expanding TAM (banking, wealth, prediction markets, tokenization, international); record June volumes; regulatory "Trump bump" (PFOF preserved, Pattern Day Trader rule removed).
Bear: Valuation (P/E ~52x) already prices a lot of good news — the average analyst target sits below the July price; heavy reliance on volatile transaction/crypto revenue; intense competition (Schwab, IBKR, Coinbase, Kraken, Kalshi, Polymarket); regulatory risk (Florida crypto-marketing probe, Lithuania tokenized-equity review, >$80m of 2023–25 fines); crypto-downturn drag.
SECTION 5 — Signal Context: Illumina (NASDAQ: ILMN)
Factual background only, for context on a chart-based trend-following ("Turtle") setup (noted entry 184.90–188.68, stop below 155.55, targets 226.42 and 283.02). This is not a recommendation or validation of the trade.
Business: Illumina is the dominant provider of DNA sequencing systems and consumables (NovaSeq X, MiSeq i100), plus arrays and a growing software/multiomics business (DRAGEN analysis, SomaLogic proteomics). Reuters (29 June 2026) noted analysts "estimate [Illumina] dominates 70% of the market." CEO Jacob Thaysen is pivoting the company toward clinical sequencing (now >65% of consumables revenue, growing ~20% y/y) to reduce dependence on volatile academic-research funding.
Price/valuation: ILMN was setting fresh 52-week highs in the low-to-mid $180s in late June/early July 2026 (52-week range ~$88–$189), having roughly doubled off its 2025 lows (~80% one-year total return). P/E ~34x, EPS TTM ~$5.5, no dividend.
Q1 2026 (reported 30 April): revenue $1.09bn (+4.8% y/y, beat); non-GAAP EPS $1.15 (beat); GAAP EPS $0.87; >80 NovaSeq X placements. Guidance raised: FY2026 revenue $4.52–4.62bn, non-GAAP EPS $5.15–5.30, operating margin 23.4–23.6%. Board added $1.5bn to the buyback. Q2 2026 revenue guided $1.12–1.14bn, EPS $1.20–1.25. Next earnings: 30 July 2026.
Recent catalysts:
Roche launched its Axelios sequencer (29 June 2026) using proprietary "sequencing by expansion" chemistry at a $750,000 list price (vs NovaSeq X ~$985k–$1.25m). Per GenomeWeb (AGBT 2026), Axelios 1 "can sequence a standard human genome at 30X coverage in the duplex output mode for $150," with Roche's Lauer noting: "This is not any discount. This is the list price." It offers same-day whole-genome sequencing and is research-use-only at launch — the most credible new competitive threat; JPMorgan notes Illumina's clinical base is "sticky."
China: placed Illumina on its Unreliable Entities List (Feb 2025) and banned sequencer imports (March 2025); the import ban was lifted November 2025, but Illumina remains on the UEL (not fully resolved). China is now ~3% of revenue.
GRAIL: spun off June 2024 (Illumina retains ~14.5%); EU antitrust and SEC overhangs resolved.
Icahn proxy fight: historical/resolved (2023) — no active battle.
New board members: David King (ex-Labcorp) and Daniel Skovronsky (Eli Lilly CSO, June 2026).
Analyst targets (wide dispersion): bulls raised targets into the launch — Guggenheim $200 (Buy), Piper Sandler $200 (Overweight), JPMorgan $185 (upgraded to Overweight), Bernstein $185 (Market Perform), RBC $170 (Outperform); bears Barclays $145 (Underweight) and Citi $95 (Sell). Published average targets (~$142–152) lag the newest upgrades and sit below the early-July price, implying limited near-term upside in consensus eyes.
Competitors: Roche (Axelios), Ultima Genomics (~$100 genome), Element Biosciences (AVITI/Vitari), MGI/Complete Genomics (strong in China), plus long-read players Oxford Nanopore and PacBio.
Recommendations (educational next steps, not advice)
Watch the 28–29 July FOMC and the July inflation prints. The market is split between hike and hold. A benchmark to change your view: if core PCE resumes falling toward 3% and payrolls stay soft, the hold/eventual-cut narrative strengthens (risk-on, dollar softer, gold firmer). If inflation re-accelerates, hike risk returns (risk-off for long-duration tech).
Treat the AI trade as intact-but-fragile. Fundamentals (capex, backlogs) support leadership, but position sizing should assume sharp valuation-driven drawdowns like the 30 June–2 July chip selloff. A break in hyperscaler capex guidance or weak Q2 AI-revenue prints would be the signal to reduce exposure.
For HOOD, separate the narrative from the price. The Trump Accounts/diversification story is real, but consensus targets sit below the current price. Benchmarks: watch the 29 July Q2 print for prediction-market and net-deposit growth, and whether crypto revenue stabilises.
On ILMN context: the 30 July earnings and the competitive response to Roche's Axelios are the key dated catalysts to be aware of around any trend position.
Caveats
Provisional/holiday-distorted data: the jobs report was pulled forward to Thursday 2 July; US markets were closed Friday 3 July, so "weekly" index moves are measured to Thursday's close. Payroll figures are subject to revision (April/May were already cut a combined 74k).
Conflicting figures flagged: Nvidia's forward P/E is cited anywhere from ~32x to ~43x depending on source and earnings basis; HOOD's average analyst target ranges ~$105–117 across trackers; ILMN's "consensus" target (~$142–152) lags a wave of June/July upgrades to $185–200.
Forward-looking language: hyperscaler capex, Roche's Axelios sales targets, and all price targets are projections, not outcomes. Bank forecasts for gold/oil are speculative.
Compliance: This newsletter is educational and general in nature. It is not personalised investment advice, not a recommendation to buy or sell any security, and contains no guarantee of returns. Trading involves risk of loss; do your own research.